Sinovac to Test Covid-19 Vaccine on 9,000 Health Care Workers in Brazil
What’s new: China’s Sinovac Biotech Ltd. plans to start large-scale human trials of a potential coronavirus vaccine in Brazil this month.
Brazilian medical research center Instituto Butantan will sponsor the phase 3 clinical trials on nearly 9,000 health care workers across 12 sites, the company said in a statement Monday.
Each site still needs to give ethical approval before the trials can go ahead, and the test subjects will need to be recruited.
The background: The Brazilian Health Regulatory Agency, known as Anvisa, granted approval on Friday for a large-scale trial of Sinovac’s inactivated Covid-19 vaccine, known as CoronaVac.
CoronaVac went into development on Jan. 28, and early trials on healthy people in China have shown no “serious” adverse responses, with nine in 10 subjects producing detectable levels of coronavirus-fighting antibodies after two jabs, the company said.
Brazil has emerged as the country second-hardest hit by Covid-19. The South American nation’s epidemic continues to grow after it reported an astonishing 263,337 new cases last week, more than three times the official total caseload in China where the outbreak began.
Quick Takes are condensed versions of China-related stories for fast news you can use.
Contact reporter Flynn Murphy (firstname.lastname@example.org)
- MOST POPULAR